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Purpose/Objective: Irradiation of the internal mammary 
chain (IMC) of lymph nodes may increase local control and 
overall survival for breast cancer. However, including the IMC 
in the treatment volume can significantly increase the doses 
to OARs, so these improvements could be outweighed by 
increased risk of late toxicities. Doses to cardiopulmonary 
volumes can be reduced for photon breast radiotherapy, even 
when IMC nodes are included in the PTV, by delivering 
treatment only during deep inspiration, but the benefits of 
respiratory gating for proton breast radiotherapy have not 
been examined. This study evaluates the doses to OARs for 
proton radiotherapy of the breast and IMC during free 
breathing (FB) and maximum inspiration (MI). 
Materials and Methods: Gated and free-breathing CT scans 
were obtained for 18 patients. The CTVs and PTVs for the IMC 
and breast, and the OARs (heart, contralateral breast and 
ipsi- and contra-lateral lung) were outlined. The PTVIMC, 
excluding the volume overlapping PTVBreast, and PTVBreast were 
prescribed doses of 40 Gy and 50 Gy respectively. 
Treatments were planned with Eclipse v13 for four proton 
fields ranging from -40° to 75° delivered via spot-scanning. 
Plans were optimised to minimise doses to the ipsilateral lung 
and heart whilst ensuring PTV coverage met the constraints 
that V95% ≥ 95% and V107% ≤ 2% of the prescribed dose. The 
homogeneity index (HI) of CTV coverage was characterised as 
(D98% - D2%)/prescribed dose. Mean doses to the OARs, V5Gy 
and V20Gy for each lung, and V5Gy and V22.5Gy for the heart were 
calculated. Dose metrics for CTVs and OARs for plans on 
paired MI and FB datasets were compared using Student's t-
tests. Doses to CTVIMC were evaluated excluding the volumes 
overlapped by PTVBreast. 
Results: All plans met the criteria for PTV coverage. Metrics 
for CTVs and OARs are shown in Table 1 and a typical dose 
distribution, including PTVBreast (red contour) and PTVIMC (blue 
contour), is shown in Figure 1. The doses to OARs differed 
significantly between paired plans, with higher doses to the 
ipsilateral lung but lower doses to the heart for gated 
compared with free-breathing plans. Homogeneity of CTV 
coverage also differed significantly, although mean CTV doses 
did not. The higher HI for CTVIMC than CTVBreast is due to the 
dose gradient at the border between PTVBreast and CTVIMC. 
 
 
 
 
Conclusions: Proton radiotherapy for breast treatments can 
achieve highly uniform target coverage whilst delivering low 
doses to OARs. Gating on the maximum inspiration phase of 
respiration has the potential to further reduce heart doses 
whilst slightly increasing doses to the ipsilateral lung. 
However, the robustness of the dose distributions to 
respiratory motion and patient positioning errors may also 
differ between free-breathing and gated treatments, and will 
be investigated in future work. 
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Purpose/Objective: In prostate SBRT the proximity to PTV of 
organs at risk represent a formidable challenge in order to 
ensure the respect of clinical dose constraints. Moreover, 
there are no objective criteria relative to the degree of 
conformity or homogeneity of dose in PTV to determine 
whether an optimal plan has been achieved, so there could 
be inter-planner differences due to the subjective judgement 
of plan’s quality. In this study, a dosimetric quality 
assessment of the first 40 clinical VMAT plans for prostate 
SBRT is presented with the goal to identify the most efficient 
quantitative metrics for plan quality evaluation and to 
improve inter-planner consistency.  
Materials and Methods: Since 2012, 40 patients at 
low/intermediate risk for localized prostate cancer have 
been planned for SBRT. Fraction size is 6 Gy for 7 fractions, 
